Award details

Pre-commercialisation validation of Stem Cell Generator as a highly efficient single transfection iPSC reprogramming vector

Reference	BB/J010901/1
Principal Investigator / Supervisor	Professor Tyson Sharp
Co-Investigators / Co-Supervisors	Professor Tristan McKay
Institution	Queen Mary University of London
Department	Barts Cancer Institute
Funding type	Research
Value (£)	114,530
Status	Completed
Type	Research Grant
Start date	01/06/2012
End date	30/11/2013
Duration	18 months

Abstract

unavailable

Summary

Pluripotent stem cells are the cornerstone of Regenerative Medicine; a potentially limitless supply of cells that can be differentiated into virtually any cell type in the human body for use in cell therapy and transplantation. Human Embryonic Stem (ES) cells are already being used in clinical trials to treat eye disease and spinal cord injury but the necessity for immune suppression and ethical contention limit their widespread application. The emergence of induced Pluripotent Stem (iPS) cell technology means that a patients own skin cells can be genetically reprogrammed to pluripotency by the expression of just four key genes. This technology is currently precluded from clinical use because two of the four genes have been shown to cause cancer. We have developed a new way of generating iPS cells that does not use the two cancer causing genes. We have shown that this method is also more efficient at making iPS cells and we hope that it will expedite a route to clinical application.

Committee	Not funded via Committee
Research Topics	Stem Cells
Research Priority	X – Research Priority information not available
Research Initiative	Follow-On Fund (FOF) [2004-2015]
Funding Scheme	X – not Funded via a specific Funding Scheme

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search